| Account | Shares | Price | Value | % of acct | Cost/sh | Gain $ | Gain % | Target |
|---|---|---|---|---|---|---|---|---|
| RLT | 28 | $55.00 | $1,540 | 0.09% | $43.32 | $327 | +27.0% | — |
| ROTH | 23 | $55.00 | $1,265 | 0.49% | $43.29 | $269 | +27.1% | — |
| Total | 51 | $2,805 | 0.06% | $597 | +27.0% | — |
In short: Upgraded to overweight at Morgan Stanley today, target to 63 from 46 (it had blown past the prior target), citing "a strong mix of visible growth and pipeline upside." Harrington owns it and is torn — by her own rules, not the fundamentals: "they've got strong oncology, they've got everything going for them other than for us, because frankly it's done so well. It's up 13% year to date and we've had it for a while now. We're down to a 3% dividend yield. So now our question becomes, does it still fit the strategy? That's always the challenge — once these companies start to really pick up steam, sometimes the valuation no longer makes sense for us. Trading at 16 times, great growth ahead, great stock… but, OK, we've got that discipline."
Morgan Stanley upgraded Roche and raised its target to 63 from 46, citing strong oncology, visible growth and pipeline upside. Jenny Harrington owns it — and her problem is success. Her strategy is built around dividend income, and as the shares have risen 13% this year the yield has fallen to 3%.
"They've got everything going for them other than for us… once these companies start to really pick up steam, sometimes the valuation no longer makes sense for us. Trading at 16 times, great growth ahead, great stock — but we've got that discipline." A good illustration that a sell decision can be about a mandate rather than a judgment on the company.
In short: Europe's #2 (~$330B pharma) in the Europe-top-5 table — reference for the no-tech, slow-growth argument.
17:42After ASML is Roche with a market cap of 330 billion which is a pharma company. Then LVMH 295 billion and a consumer discretionary luxury company. Then Novartis at 290 billion and a pharma company. And number five is Nestlé at 260 billion and a consumer staples food company. By contrast, the market cap of the top five stocks in the US range from 2.7 trillion to 5.1 trillion.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.